Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...
The drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with ...
Chronic Kidney Disease (CKD) affects approximately 15% of U.S. adults and as many as 9 in 10 with CKD are unaware they have ...
News-Medical.Net on MSN1d
Tirzepatide improves kidney, cardiovascular function in patients with obesity and HFpEFThe drug tirzepatide improved kidney function and cardiovascular outcomes among patients with obesity and heart failure with preserved ejection fraction (HFpEF) compared with placebo at one year, ...
Results from the SUMMIT trial suggest that tirzepatide is as effective in preventing heart failure events in those with ...
Midland Daily News on MSN5d
Savvy Senior: Are you at risk for kidney disease?Anyone who has diabetes, high blood pressure, heart problems or has a family history of the disease is at increased risk for ...
Findings from the American College of Cardiology 2025 Annual Scientific Session show oral semaglutide reduces the risk of heart attack, stroke, and cardiovascular death by 14% in patients with type 2 ...
In the SOUL trial, Rybelsus produced a 14% risk reduction of major adverse cardiovascular events in patients with type 2 ...
American Heart Association on MSN2d
Poor sleep linked to advanced stages of a complex heart and kidney disease syndromePeople with a complex heart, kidney and metabolic-related condition who got better quality sleep were less likely to have an ...
Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback